SCHEMBL24196106

SCHEMBL24196106

N#Cc1nc(Nc2ccc(I)cc2F)c(C(=O)NO)cc1F

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAP2K1 Q02750 17/20 0.48
▸ IDO1 P14902 1/20 0.42
▸ MAP2K2 P36507 9/20 0.41
▸ HDAC3 O15379 3/20 0.38
▸ HDAC1 Q13547 3/20 0.38
▸ HDAC6 Q9UBN7 3/20 0.38
▸ HDAC4 P56524 2/20 0.38
▸ HDAC7 Q8WUI4 2/20 0.38
▸ HDAC2 Q92769 2/20 0.38
▸ HDAC10 Q969S8 2/20 0.38
▸ HDAC11 Q96DB2 2/20 0.38
▸ HDAC8 Q9BY41 2/20 0.38
▸ HDAC9 Q9UKV0 2/20 0.38
▸ HDAC5 Q9UQL6 2/20 0.38
▸ PRKCZ Q05513 1/20 0.37
▸ IARS2 Q9NSE4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23851383 0.88 MAP2K1 (0.59) MAP2K1IDO1MAP2K2
SCHEMBL31135614 0.88 MAP2K1 (0.59) MAP2K1IDO1MAP2K2
SCHEMBL24196109 0.87 HDAC1 (0.39) MAP2K1MAP2K2HDAC3HDAC1HDAC6
SCHEMBL24195905 0.86 MAP2K1 (0.50) MAP2K1MAP2K2HDAC3HDAC1HDAC6
SCHEMBL31135631 0.85 MAP2K1 (0.50) MAP2K1IDO1MAP2K2
SCHEMBL23850846 0.85 MAP2K1 (0.50) MAP2K1IDO1MAP2K2
SCHEMBL24196125 0.85 MAP2K1 (0.55) MAP2K1MAP2K2HDAC3HDAC1HDAC6
SCHEMBL24195795 0.84 MAP2K1 (0.65) MAP2K1MAP2K2
SCHEMBL24195910 0.84 MAP2K1 (0.65) MAP2K1MAP2K2
SCHEMBL24195902 0.84 MAP2K1 (0.51) MAP2K1IDO1MAP2K2HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572344-B2 Cyanoaryl-aniline compounds for treatment of dermal disorders NFLECTION THERAPEUTICS, INC. (US) 2023-02-07 — — US disclosed
US-20220009887-A1 CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS NFLECTION THERAPEUTICS, INC. 2022-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220009887-A1 CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS TYR, CUTA, BRAF MAP2K1 469/4885IDO1 341/4885MAP2K2 291/4885
US-11572344-B2 Cyanoaryl-aniline compounds for treatment of dermal disorders TYR, CUTA, BRAF MAP2K1 469/4885IDO1 341/4885MAP2K2 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback